July 21, 2024
4 min watch
Save
VIDEO: Axitinib implant addresses sustainability in wet AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.
Dugel explained how the implant is designed to address unmet needs in sustainability.
“We firmly believe that not only will we improve sustainability and be able to treat a lot more patients who deserve this treatment, but we believe that we will also be able to improve outcomes,” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dugel reports being executive chairman, CEO and president of Ocular Therapeutix.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.